Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Assessment of statistical significance and clinical relevance.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.
Extoxnet (extension toxicology network), 4-aminopyridine
Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing-Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Roche reports positive studies of MabThera given by subcutaneous injection
Copolymer 1 inhibits manifestations of graft rejection.
Takeda Submits a New Drug Application for Glatiramer Acetate in Japan for the Relapse Prevention of Multiple Sclerosis
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
First proof for rituximab in IgG4-related disease
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
Idebenone for primary progressive multiple sclerosis
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Company restores access to multiple sclerosis drug after pressure from neurologists.
4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis.

Pages